Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 6/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 5/20 | 0.93 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.93 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745374 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL19557590 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL15593220 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13317732 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL10028909 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL14268489 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL4319863 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL2435520 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13848041 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL2434435 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | claimed |
| WO-2016110702-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | ISIS INNOVATION LIMITED (GB) | 2016-07-14 | — | — | WO | claimed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | claimed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | claimed |
| EP-2556163-A1 | HIGH MANNOSE GLYCANS | Momenta Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | claimed |
| WO-2011127322-A1 | HIGH MANNOSE GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | claimed |
| EP-2182936-A2 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2010-05-12 | — | — | EP | claimed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | claimed |
| US-20100004156-A1 | Small Compounds That Correct Protein Misfolding and Uses Thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2010-01-07 | — | — | US | claimed |
| US-5643888-A | Regulating retroviral replication, infection, and pathogenesis | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1997-07-01 | — | — | US | claimed |
| EP-0561820-B1 | CONTROL OF PARASITIC NEMATODES | BRITISH TECH GROUP (GB) | 1996-03-20 | — | — | EP | claimed |
| EP-0252962-B1 | REGULATING RETROVIRAL REPLICATION, INFECTION, AND PATHOGENESIS | HUTCHINSON FRED CANCER RES (US) | 1995-08-23 | — | — | EP | claimed |
| US-5376675-A | Applying 2R,5R-dihydroxymethyl-3R,4R-dihydroxypyrrolidine | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-12-27 | — | — | US | claimed |
| US-5264356-A | Regulating retroviral replication, infection, and pathogenesis | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1993-11-23 | — | — | US | claimed |
| EP-0561820-A1 | CONTROL OF PARASITIC NEMATODES (A). | BRITISH TECH GROUP (GB) | 1993-09-29 | — | — | EP | claimed |
| EP-0252962-A4 | REGULATING RETROVIRAL REPLICATION, INFECTION, AND PATHOGENESIS | — | 1992-09-09 | — | — | EP | claimed |
| WO-1992009202-A1 | CONTROL OF PARASITIC NEMATODES (A) | BRITISH TECHNOLOGY GROUP LTD (GB) | 1992-06-11 | — | — | WO | claimed |
| EP-0252962-A1 | REGULATING RETROVIRAL REPLICATION, INFECTION, AND PATHOGENESIS. | HUTCHINSON FRED CANCER RES (US) | 1988-01-20 | — | — | EP | claimed |
| WO-1987003903-A1 | REGULATING RETROVIRAL REPLICATION, INFECTION, AND PATHOGENESIS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1987-07-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | UGCG, SMPD1, SMPD4 | GLA 731/4885AGL 870/4885GAA 52/4885 |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | GLA 467/4885AGL 252/4885GAA 11/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | GLA 99/4885AGL 346/4885GAA 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.